US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
JP2008507294A
(ja)
|
2004-07-26 |
2008-03-13 |
ダウ グローバル テクノロジーズ インコーポレイティド |
菌株遺伝子操作による改善されたタンパク質発現のための方法
|
PT1789442E
(pt)
*
|
2004-09-02 |
2009-11-11 |
Lilly Co Eli |
Muteínas do factor de crescimento de fibroblasto 21
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
KR100888022B1
(ko)
*
|
2006-12-21 |
2009-03-09 |
재단법인 목암생명공학연구소 |
면역글로불린 Fc와 인간 아포리포단백질(a)크링글절편의 융합단백질 LK8Fc
|
KR20140012199A
(ko)
|
2007-03-30 |
2014-01-29 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
AU2008245696B2
(en)
|
2007-04-27 |
2013-11-07 |
Pelican Technology Holdings, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
EP2185178B1
(en)
|
2007-08-03 |
2017-08-23 |
Eli Lilly And Company |
Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
|
JOP20190083A1
(ar)
*
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
EP2358749B1
(en)
*
|
2008-10-10 |
2018-07-18 |
Amgen, Inc |
Fgf21 mutants and uses thereof
|
MX2011007544A
(es)
|
2009-01-23 |
2011-08-12 |
Novo Nordisk As |
Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso.
|
DK3248610T3
(da)
*
|
2009-05-05 |
2024-01-15 |
Amgen Inc |
Fgf21-mutanter og anvendelser deraf
|
AU2010246038A1
(en)
|
2009-05-05 |
2011-12-01 |
Amgen Inc. |
FGF21 mutants and uses thereof
|
WO2011154349A2
(en)
|
2010-06-08 |
2011-12-15 |
Novo Nordisk A/S |
Fgf21 analogues and derivatives
|
EP2443145A1
(en)
*
|
2009-06-17 |
2012-04-25 |
Amgen, Inc |
Chimeric fgf19 polypeptides and uses thereof
|
CN102656266B
(zh)
*
|
2009-10-15 |
2016-08-03 |
霍夫曼-拉罗奇有限公司 |
具有改变的受体特异性的嵌合成纤维细胞生长因子
|
AU2010326024A1
(en)
|
2009-12-02 |
2012-07-05 |
Amgen Inc. |
Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
EP2359843A1
(en)
|
2010-01-21 |
2011-08-24 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
EP2558497A2
(en)
|
2010-04-15 |
2013-02-20 |
Amgen Inc. |
Human fgf receptor and beta-klotho binding proteins
|
CA2796459C
(en)
|
2010-04-16 |
2016-05-24 |
Salk Institute For Biological Studies |
Methods for treating metabolic disorders using fgf-1
|
WO2012010553A1
(en)
*
|
2010-07-20 |
2012-01-26 |
Novo Nordisk A/S |
N-terminal modified fgf21 compounds
|
SG190082A1
(en)
*
|
2010-11-05 |
2013-06-28 |
Covx Technologies Ireland Ltd |
Anti-diabetic compounds
|
US9023791B2
(en)
*
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
EP2726092B1
(en)
|
2011-06-28 |
2019-06-19 |
Inhibrx, LP |
Serpin fusion polypeptides and methods of use thereof
|
KR102077721B1
(ko)
|
2011-07-01 |
2020-02-14 |
엔지엠 바이오파마슈티컬스, 아이엔씨. |
대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
|
EP2548570A1
(en)
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
JO3476B1
(ar)
*
|
2011-09-26 |
2020-07-05 |
Novartis Ag |
بروتينات مندمجة لعلاج الاضطرابات الايضية
|
SG11201402640SA
(en)
|
2011-12-22 |
2014-10-30 |
Pfizer |
Anti-diabetic compounds
|
RS57827B1
(sr)
|
2012-02-15 |
2018-12-31 |
Novo Nordisk As |
Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
|
LT2814844T
(lt)
|
2012-02-15 |
2017-10-25 |
Novo Nordisk A/S |
Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
WO2013131091A1
(en)
|
2012-03-02 |
2013-09-06 |
New York University |
Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
|
US9474785B2
(en)
|
2012-06-07 |
2016-10-25 |
New York University |
Chimeric fibroblast growth factor 19 proteins and methods of use
|
US9464126B2
(en)
|
2012-06-07 |
2016-10-11 |
New York University |
Chimeric fibroblast growth factor 21 proteins and methods of use
|
US9657075B2
(en)
|
2012-06-07 |
2017-05-23 |
New York University |
Chimeric fibroblast growth factor 23 proteins and methods of use
|
TWI513705B
(zh)
*
|
2012-06-11 |
2015-12-21 |
Lilly Co Eli |
纖維母細胞生長因子21蛋白質
|
AU2013274639A1
(en)
|
2012-06-11 |
2014-11-06 |
Eli Lilly And Company |
Fibroblast growth factor 21 variants
|
EP2864352B1
(en)
*
|
2012-06-22 |
2018-08-08 |
The Trustees Of Dartmouth College |
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
WO2014085365A2
(en)
|
2012-11-28 |
2014-06-05 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
CN108888757A
(zh)
|
2012-12-27 |
2018-11-27 |
恩格姆生物制药公司 |
用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
|
US9550820B2
(en)
|
2013-02-22 |
2017-01-24 |
New York University |
Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
|
US20160235810A1
(en)
|
2013-10-18 |
2016-08-18 |
Novartis Ag |
Methods of treating diabetes and related disorders
|
CN105828833A
(zh)
|
2013-10-21 |
2016-08-03 |
萨克生物研究学院 |
突变的成纤维细胞生长因子(fgf)1及使用方法
|
WO2015065897A1
(en)
|
2013-10-28 |
2015-05-07 |
Ngm Biopharmaceuticals, Inc. |
Cancer models and associated methods
|
MX369173B
(es)
|
2013-12-24 |
2019-10-30 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista.
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
RU2701434C2
(ru)
|
2014-01-24 |
2019-09-26 |
Нгм Биофармасьютикалс, Инк. |
Связывающие белки и способы их применения
|
JP6712230B2
(ja)
|
2014-03-11 |
2020-06-17 |
ノバルティス アーゲー |
リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
|
US10398758B2
(en)
|
2014-05-28 |
2019-09-03 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
|
CN107073109B
(zh)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Vista激动剂和拮抗剂抑制或增强体液免疫的用途
|
WO2015195509A2
(en)
|
2014-06-16 |
2015-12-23 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
AU2015279525A1
(en)
*
|
2014-06-24 |
2016-12-15 |
Novo Nordisk A/S |
MIC-1 fusion proteins and uses thereof
|
MX2017000484A
(es)
|
2014-07-17 |
2017-05-01 |
Novo Nordisk As |
Mutagenesis dirigida al sitio anticuerpos receptor desencadenante expresado en las celulas mieloides de tipo 1 (trem-1) para reducir la viscosidad.
|
EP3209681A4
(en)
|
2014-10-23 |
2018-10-31 |
NGM Biopharmaceuticals, Inc. |
Pharmaceutical compositions comprising peptide variants and methods of use thereof
|
KR20240024362A
(ko)
|
2014-10-24 |
2024-02-23 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 fgf-21 폴리펩티드 및 그의 용도
|
WO2016073855A1
(en)
|
2014-11-07 |
2016-05-12 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
PT3236991T
(pt)
|
2014-12-23 |
2019-09-06 |
Novo Nordisk As |
Derivados de fgf21 e usos dos mesmos
|
KR20160088656A
(ko)
*
|
2015-01-16 |
2016-07-26 |
주식회사유한양행 |
지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
WO2017019957A2
(en)
|
2015-07-29 |
2017-02-02 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
JP2018535964A
(ja)
|
2015-10-30 |
2018-12-06 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
線維芽細胞増殖因子(fgf)1アナログによるステロイド誘導性高血糖の処置
|
US10744185B2
(en)
|
2015-11-09 |
2020-08-18 |
Ngm Biopharmaceuticals, Inc. |
Methods of using variants of FGF19 polypeptides for the treatment of pruritus
|
BR112018016461A2
(pt)
|
2016-02-12 |
2019-10-01 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
|
MX2018012469A
(es)
|
2016-04-15 |
2019-07-04 |
Immunext Inc |
Anticuerpos vista antihumanos y uso de los mismos.
|
BR112018072034A2
(pt)
|
2016-05-24 |
2019-02-12 |
Novo Nordisk A/S |
compostos mic-1 e usos dos mesmos
|
EP3502143A4
(en)
|
2016-08-19 |
2020-07-15 |
Ampsource Biopharma Shanghai Inc. |
BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
|
CN106279437B
(zh)
|
2016-08-19 |
2017-10-31 |
安源医药科技(上海)有限公司 |
高糖基化人凝血因子viii融合蛋白及其制备方法与用途
|
CN106317226B
(zh)
|
2016-08-19 |
2017-09-05 |
安源医药科技(上海)有限公司 |
用于构建融合蛋白的连接肽
|
WO2018039557A1
(en)
|
2016-08-26 |
2018-03-01 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
EP3596130A4
(en)
*
|
2017-03-14 |
2020-12-30 |
Sunshine Lake Pharma Co., Ltd. |
DOUBLE TARGET FUSION PROTEINS WITH FC PORTION OF AN IMMUNE LOBULIN
|
EP3604328A4
(en)
|
2017-03-23 |
2021-01-06 |
Hanmi Pharm. Co., Ltd. |
REDUCED INSULIN ANALOGUE COMPLEX FOR INSULIN RECEPTOR AND ITS USE
|
TWI710377B
(zh)
|
2017-05-23 |
2020-11-21 |
丹麥商諾佛 儂迪克股份有限公司 |
Mic-1化合物及其用途
|
SG11202001379WA
(en)
|
2017-09-08 |
2020-03-30 |
Bristol Myers Squibb Co |
Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
|
CA3090335A1
(en)
*
|
2018-02-06 |
2019-08-15 |
Vancouver Biotech Ltd. |
Use of ghr-106 monoclonal antibody as a gnrh antagonist
|
CN116098989A
(zh)
|
2018-02-08 |
2023-05-12 |
广东东阳光药业有限公司 |
Fgf21变体、融合蛋白及其应用
|
EA202092302A1
(ru)
|
2018-04-02 |
2021-02-02 |
Бристол-Майерс Сквибб Компани |
Антитела к trem-1 и их применения
|
CN114903978A
(zh)
|
2018-07-03 |
2022-08-16 |
百时美施贵宝公司 |
Fgf-21配制品
|
CN111195349B
(zh)
*
|
2018-11-16 |
2023-02-24 |
鲁南制药集团股份有限公司 |
一种代谢调节融合蛋白的冻干粉制剂
|
CN111944055B
(zh)
|
2019-05-16 |
2022-08-02 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的融合蛋白
|
US11542309B2
(en)
|
2019-07-31 |
2023-01-03 |
Salk Institute For Biological Studies |
Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
|
TW202140074A
(zh)
|
2020-01-08 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
Fgf-21結合物調配物
|
CN115322794A
(zh)
|
2020-01-11 |
2022-11-11 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
US11981718B2
(en)
|
2020-05-27 |
2024-05-14 |
Ampsource Biopharma Shanghai Inc. |
Dual-function protein for lipid and blood glucose regulation
|
WO2022032187A1
(en)
|
2020-08-07 |
2022-02-10 |
Bristol-Myers Squibb Company |
Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
|
WO2022115597A1
(en)
|
2020-11-25 |
2022-06-02 |
Bristol-Myers Squibb Company |
Methods of treating liver diseases
|